Connor Clark & Lunn Investment Management Ltd. Acquires 17,654 Shares of Eton Pharmaceuticals, Inc. $ETON

Connor Clark & Lunn Investment Management Ltd. lifted its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 8.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 232,532 shares of the company's stock after buying an additional 17,654 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.87% of Eton Pharmaceuticals worth $3,018,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Nantahala Capital Management LLC increased its holdings in shares of Eton Pharmaceuticals by 12.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock worth $14,898,000 after buying an additional 119,750 shares during the period. Mink Brook Asset Management LLC purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $6,071,000. Parkman Healthcare Partners LLC increased its stake in shares of Eton Pharmaceuticals by 6.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company's stock valued at $3,688,000 after buying an additional 16,664 shares during the period. Renaissance Technologies LLC increased its stake in shares of Eton Pharmaceuticals by 131.5% during the fourth quarter. Renaissance Technologies LLC now owns 193,100 shares of the company's stock valued at $2,572,000 after buying an additional 109,700 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $1,850,000. Hedge funds and other institutional investors own 27.86% of the company's stock.

Eton Pharmaceuticals Stock Down 2.2%

Shares of ETON stock traded down $0.38 during midday trading on Monday, reaching $16.67. 159,392 shares of the stock were exchanged, compared to its average volume of 368,788. Eton Pharmaceuticals, Inc. has a 1 year low of $3.96 and a 1 year high of $21.48. The company's 50 day moving average is $14.83 and its two-hundred day moving average is $15.46. The company has a current ratio of 1.77, a quick ratio of 1.16 and a debt-to-equity ratio of 1.14. The firm has a market cap of $446.96 million, a PE ratio of -103.93 and a beta of 1.13.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.09). The company had revenue of $18.93 million during the quarter, compared to the consensus estimate of $16.71 million. Eton Pharmaceuticals had a negative return on equity of 0.73% and a negative net margin of 7.10%. On average, equities research analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Wall Street Analyst Weigh In

ETON has been the topic of several research analyst reports. Wall Street Zen cut Eton Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. B. Riley reiterated a "buy" rating and set a $26.00 target price (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and set a $35.00 target price (up previously from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Finally, Craig Hallum upped their target price on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, insider David Krempa sold 10,223 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $14.73, for a total value of $150,584.79. Following the sale, the insider owned 612,646 shares in the company, valued at $9,024,275.58. This represents a 1.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 34,000 shares of company stock valued at $504,318. Corporate insiders own 14.89% of the company's stock.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.